News
HUMA
0.7182
+1.21%
0.0086
Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates
NASDAQ · 5d ago
Weekly Report: what happened at HUMA last week (0727-0731)?
Weekly Report · 6d ago
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
TipRanks · 07/31 21:31
Buy Rating Reaffirmed on Humacyte as FDA Clears First-in-Human CABG Study; $2 Price Target Maintained
TipRanks · 07/29 11:27
Humacyte Wins FDA IND Clearance For First-In-Human Coronary Bypass Trial; Stock Up
NASDAQ · 07/27 15:16
Humacyte announces FDA acceptance of CTEV IND application
TipRanks · 07/27 12:25
Weekly Report: what happened at HUMA last week (0720-0724)?
Weekly Report · 07/27 10:12
Weekly Report: what happened at HUMA last week (0713-0717)?
Weekly Report · 07/20 10:09
BTIG Keeps Their Buy Rating on Humacyte (HUMA)
TipRanks · 07/14 11:25
Weekly Report: what happened at HUMA last week (0706-0710)?
Weekly Report · 07/13 10:11
Weekly Report: what happened at HUMA last week (0629-0703)?
Weekly Report · 07/06 10:14
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/01 21:05
Weekly Report: what happened at HUMA last week (0622-0626)?
Weekly Report · 06/29 10:09
Weekly Report: what happened at HUMA last week (0615-0619)?
Weekly Report · 06/22 10:17
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
NASDAQ · 06/19 13:30
Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)
TipRanks · 06/18 11:28
Humacyte Price Target Cut to $1.25/Share From $1.50 by TD Cowen
Dow Jones · 06/17 14:10
Humacyte Is Maintained at Buy by TD Cowen
Dow Jones · 06/17 14:10
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25
Benzinga · 06/17 14:00
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen
TipRanks · 06/17 12:32
More
Webull provides a variety of real-time HUMA stock news. You can receive the latest news about Humacyte Inc through multiple platforms. This information may help you make smarter investment decisions.
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.